Page last updated: 2024-12-08
lotaustralin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
lotaustralin: higher homologue of linamarin from flax; a cyanogenic glycoside; RN given refers to (R)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 441467 |
CHEBI ID | 6542 |
SCHEMBL ID | 42924 |
MeSH ID | M0041788 |
Synonyms (25)
Synonym |
---|
2(r)-hydroxy-2-methylbutyronitrile-beta-d-glucopyranoside |
p588137a94 , |
butanenitrile, 2-(beta-d-glucopyranosyloxy)-2-methyl-, (r)- |
unii-p588137a94 |
534-67-8 |
C08334 , |
lotaustralin |
2-hydroxy-2-methylbutyronitrile-beta-d-glucopyranoside |
AC1L9B81 , |
(2r)-2-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutanenitrile |
2-methyl-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutanenitrile |
butanenitrile, 2-(.beta.-d-glucopyranosyloxy)-2-methyl-, (2r)- |
.beta.-d-glucopyranosyloxy-2-methylbutyronitrile (r) |
SCHEMBL42924 |
CHEBI:6542 |
surecn42924 |
zinc04097529 |
(2r)-2-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-butanenitrile |
DTXSID30897501 |
Q905492 |
(r)-2-methyl-2-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)butanenitrile |
(r)-2-(beta-d-glucopyranosyloxy)-2-methylbutyronitrile |
(2r)-2-(beta-d-glucopyranosyloxy)-2-methyl-butanenitrile; |
(2r)-2-methyl-2-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butanenitrile |
AKOS040752682 |
Research Excerpts
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
"The toxic effects of cassava diets on humans were reviewed." | ( The toxic effects of cassava (manihot esculenta grantz) diets on humans: a review. Agunbiade, OO; Aregheore, EM, 1991) | 0.28 |
" In order to achieve safe levels of 10 μg/g in cassava products, new methods of processing, especially for cassava containing more than 250 μg CN eq." | ( Strategies for elimination of cyanogens from cassava for reducing toxicity and improving food safety. Nambisan, B, 2011) | 0.37 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
cyanogenic glycoside | A glycoside in which the aglycone contains a cyanide group. A cyanogenic glycoside can release poisonous hydrogen cyanide if acted upon by some enzyme. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Pathways (4)
Pathway | Proteins | Compounds |
---|---|---|
lotaustralin degradation | 1 | 8 |
neolinustatin bioactivation | 0 | 8 |
lotaustralin biosynthesis | 0 | 14 |
superpathway of linamarin and lotaustralin biosynthesis | 0 | 23 |
Research
Studies (31)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 7 (22.58) | 18.7374 |
1990's | 5 (16.13) | 18.2507 |
2000's | 7 (22.58) | 29.6817 |
2010's | 12 (38.71) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 30.82
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.82) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 2 (6.25%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 30 (93.75%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |